<DOC>
	<DOCNO>NCT00623077</DOCNO>
	<brief_summary>RATIONALE : A peripheral blood stem cell transplant bone marrow transplant use stem cell patient may able replace immune cell destroy chemotherapy image-guided intensity-modulated radiation therapy use kill tumor cell . PURPOSE : This phase I trial study side effect best dose bone marrow radiation therapy follow autologous stem cell transplant treat patient high-risk relapse solid tumor .</brief_summary>
	<brief_title>MT2004-30 : Tomotherapy Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose tomographic total marrow irradiation ( TMI ) give prior alkylator-intensive conditioning regimen patient high-risk relapse solid tumor . Secondary - To determine feasibility perform positron emission tomography ( PET ) scan spot radiation PET-positive lesion transplantation . - To determine change bone mineral density turnover patient treat alkylator-intensive conditioning regimen TMI . OUTLINE : - Mobilization chemotherapy peripheral blood progenitor cell ( PBPC ) collection : Patients receive ifosfamide intravenously ( IV ) etoposide IV day -100 -30 . Beginning 24 hour completion chemotherapy , patient receive filgrastim ( G-CSF ) subcutaneously ( SC ) IV blood count recover . Patients receive increase dose G-CSF SC IV daily 3 consecutive day . Beginning day -97 , patient undergo 4 collection PBPCs . Patients yield adequate number cell undergo bone marrow harvest . - Bone marrow harvest : Patients undergo bone marrow aspirate biopsy 2 week last dose G-CSF . If aspirate biopsy morphologically free tumor cell demonstrate &gt; 20 % cellularity , patient receive sargramostim ( GM-CSF ) daily 5 day follow bone marrow harvest . - Total marrow irradiation ( TMI ) tomotherapy : Patients undergo escalate dos TMI* bony site use helical tomotherapy image-guided intensity-modulated radiotherapy day -11 -9 . NOTE : *Patients primary CNS tumor receive TMI eligible receive chemotherapy hematopoietic progenitor cell rescue accordance protocol . - Conditioning regimen : Patients receive busulfan IV 2 hour four time daily day -8 -6 , high-dose melphalan IV 30 minute day -5 -4 , thiotepa IV 2 hour day -3 -2 . - Autologous CD34+ hematopoietic progenitor cell transplantation : Patients undergo reinfusion autologous G-CSF-mobilized peripheral blood bone marrow progenitor cell day 0 . Patients also receive G-CSF support begin day 0 continue blood count recover 2 consecutive day . - Post-transplantation radiotherapy : Patients may receive additional radiotherapy area know metastatic disease , PET-positive lesion , primary disease ( previously irradiate maximum tolerate dose ) , lung begin day 60 post transplantation . Patients prior lung metastasis may receive 10 fraction whole-lung irradiation . Patients may also receive additional radiotherapy primary disease maximum tolerate dose yet reach . Patients undergo bone mineral density study baseline day 60 , 120 , 180 post transplantation . Patients also undergo blood sample collection periodically study pharmacokinetic analysis busulfan . Patients undergo PET scan baseline day 60 . After completion study therapy , patient follow day 180 365 periodically thereafter .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Diagnosis Patients must histologic verification malignancy original diagnosis . Diseases include : Ewing 's Family Tumors ( ES/PNET/DSRCT ) : metastatic time diagnosis and/or relapse therapy Renal tumor : relapse ( histologyWilm 's tumor ) diagnosis ( clear cell sarcoma Rhabdoid tumor ) , Hepatoblastoma : metastatic time diagnosis and/or relapse therapy Rhabdomyosarcoma : metastatic time diagnosis and/or relapse therapy Soft tissue sarcoma : chemotherapy responsive metastatic disease chemotherapy responsive relapse disease Primary Malignant Brain Neoplasms diagnosis and/or relapse Retinoblastoma : disseminate diagnosis and/or relapse Other High Risk Metastatic Relapsed Solid Tumors : To approve two physician study committee Disease Status : Patients must either : 1 ) evidence disease 2 ) stable , nonprogressive disease ( defined nonprogressive abnormality physical exam computated tomography ( CT ) and/or magnetic resonance image [ MRI ] ) within 4 week study entry . Age : Patients must 070 year age time study entry . Performance Level : Karnofsky &gt; = 50 % patient &gt; 10 year age Lansky &gt; = 50 % patient &lt; = 10 year age . Note : Neurologic deficit patient central nervous system ( CNS ) tumor must stable minimum 1 week prior study entry . Organ Function : Hematologic : prior receive total marrow irradiation ( TMI ) patient hemoglobin &gt; 10 gm/dl platelet count &gt; 20,000/μl . Patients may receive transfusion necessary . Renal : glomerular flow rate ( GFR ) ≥ 50 ml/min/1.73m^2 serum creatinine ≤ 2.5 x upper limit normal ( ULN ) age Hepatic : aspartate aminotransferase/alanine aminotransferase ( AST ALT ) ≤ 5 x ULN bilirubin ≤ 5 x ULN Cardiac : ejection fraction &gt; 45 % clinical evidence heart failure Pulmonary : oxygen saturation &gt; 92 % rest ( room air ) Disease Status : patient progressive , nontherapy responsive disease eligible . Infection : patient active , uncontrolled infection HIV+ . Pregnancy BreastFeeding : pregnant breastfeed woman enter study . Prior Radiation Therapy : patient must eligible receive TMI via tomographic radiation therapy ( determine radiation oncology staff ) . If eligible ( due extensive prior radiation circumstance ) , patient treat study receive radiation analyze separate arm .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>childhood hepatoblastoma</keyword>
	<keyword>recurrent childhood liver cancer</keyword>
	<keyword>stage IV childhood liver cancer</keyword>
	<keyword>adult primary liver cancer</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>stage IV Wilms tumor</keyword>
	<keyword>stage V Wilms tumor</keyword>
	<keyword>rhabdoid tumor kidney</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>childhood mixed glioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood pineoblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood visual pathway glioma</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>childhood high-grade cerebellar astrocytoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebellar astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
	<keyword>recurrent retinoblastoma</keyword>
	<keyword>extraocular retinoblastoma</keyword>
	<keyword>intraocular retinoblastoma</keyword>
	<keyword>childhood renal cell carcinoma</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>